<DOC>
	<DOCNO>NCT02282449</DOCNO>
	<brief_summary>Patients cancer often require intravenous chemotherapy long periods time . Ensuring patient safe reliable access vein chemotherapy challenge , sometimes medical device require administer chemotherapy vein . A totally implanted venous access device , port , implant skin arm attach small plastic catheter enters vein . This device puncture needle need treatment test . Some type vein port rapidly inject fluid ( power injection ) , use follow-up imaging study , compute tomography , require follow cancer treatment effectiveness . There publication randomize patient discuss impact power injection upon TIVAD complication device longevity arm implantation . The investigator propose compare effectiveness power injectable non-power injectable port determine different clinical performance complication . Our result impact care provided cancer patient .</brief_summary>
	<brief_title>Power Injectable Versus Non-Power Injectable , Upper Arm , TIVAD Chemotherapy</brief_title>
	<detailed_description>Hypothesis : The null hypothesis envisions device perform similarly regard chemotherapy complication . However , power injectable population experience high flow , large volume injection , may experience complication injection extravasation port damage due vigorous injection parameter . Trial Objectives : 1 . To prospectively assess functionality complication power injectable vs. non-power injectable TIVAD cohort breast cancer patient require intravenous chemotherapy . The TIVAD randomly assign patient . 2 . Assess quality life subject two different TIVADs . 3 . Facilitate device selection future cancer patient require chemotherapy . We perform randomize , prospective clinical trial patient cancer compare non-power injectable port , Cook Vital Mini Port ( Cook Canada , Mississauga , ON ) , power injectable port , AngioDynamics Smart Port CT Mini ( AngioDynamics Inc. , Manchester , GA , USA ) . Adverse event , arm swelling , skin rash , incision dehiscence , etc. , track via online reporting system , patient registry , follow-up strategy relate image clinical assessment regular time interval . Patient Follow-up : From Insertion date , 7 day post insertion telephone interview perform . Subsequently follow obtain 3 month 12 month post port insertion . Clinical examination Venous Doppler US ( arm/neck ) Chest arm X-ray QLQC30 questionnaire QLAVD-PA questionnaire Adverse Event Record Details Follow-up : Clinical Examination : Visual inspection arm , port implantation site , neck , anterior chest . 1 . Distended arm , neck chest vein - Y/N - detail 2 . Swollen edematous arm , neck , chest - Y/N - detail 3 . Skin rash - Y/N - detail 4 . Signs arm infection - redness , swell , purulent discharge - Y/N - detail 5 . Abnormal incision site port insertion - Y/N - detail Venous Doppler Ultrasound ( arm/neck ) : Ultrasound ass vein thrombosis narrowing . Chest arm x-ray : Standard x-ray include arm least elbow axilla , full chest x-ray . QLCC30 QLAVD-PA : Quality Life survey . Adverse Events : 7 day , 3 month , 12 month , 24 month possible - The patient contact telephone determine experience adverse event .</detailed_description>
	<criteria>Consecutive patient breast cancer require intravenous chemotherapy , refer local Cancer Agency arm TIVAD , include . â€¢ Those age 16 year ; Those uncorrectable blood clot disorder ; Pregnant woman , candidate chemotherapy ; Any person active infection immunocompromised state ; Those oral intravenous antibiotic day TIVAD implantation .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Venous access device</keyword>
	<keyword>Port catheter</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>